N-acetyl-aspartyl-glutamate
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
2
Earliest trial started Apr 1, 2001 (NCT00357019)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Glutamate carboxypeptidase IIINHIBITOR
FOLH1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- isospaglumic acid
- naaga
- naaga magnesium salt
- naaga sodium salt
- naaxia
- n-acetyl-1-aspartylglutamic acid
- n-acetyl-1-aspartylglutamic acid, (l)-isomer ion
- n-acetyl-1-aspartylglutamic acid, magnesium salt
- n-acetyl-1-asp-glu
- n-acetylaspartylglutamate
- n-acetyl-aspartyl-glutamate
- n-acetyl-aspartyl-glutamate
- n-acetyl-aspartyl-glutamate
- n-acetyl-aspartyl-glutamic acid
- n-acetyl-l-alpha-aspartylglutamic acid
- n-(n-acetyl-l-alpha-aspartyl)-l-glutamic acid
- zy15106
- zy 15106
- zy-15106
- zy15109
- zy 15109
- zy-15109
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06800274 | Phase 4 | Apr 21, 2023 | University of Brescia |
| NCT00357019 | Phase 4 | Apr 1, 2001 | Laboratoires Thea, University of Padova |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Laboratoires Thea | For profit | 1 | 1 | 1 | 2001 |
| University of Brescia | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Padova | Academic/Hospital | 1 | 0 | 1 | 2001 |
3 organizations
Page 1 / 1